Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, and currently in Phase 2 and Phase 3 clinical trials
Over the past few years, peptides known as GLP-1 receptor agonists have completely reshaped the weight loss landscape
Joseph Morrison, Senior Associate With 21 years of personal injury experience, Attorney Joseph R
PlexusDx compounded semaglutide is manufactured in licensed 503A pharmacies under strict USP standards and contains identical active pharmaceutical ingredient to brand Ozempic
Novo Nordisk and Eli Lilly, whose GLP-1 diabetes drug Mounjaro is expected to be approved for weight loss this year, are facing several lawsuits in the U.S
GLP-1 Support is a natural supplement, not a drug, and doesnt contain synthetic GLP-1